Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Direct Oral Anticoagulants in elderly with multimorbidity: what precautions?].
Rev Med Suisse
October 2024
Centre universitaire de traitement et de réadaptation gériatrique, Service de gériatrie, Département de médecine, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Article Synopsis
- - Elderly patients with multiple health issues are more likely to experience problems from direct oral anticoagulants (DOAC), especially if they have kidney issues, are very old or underweight, or take many medications.
- - A medication review and assessment of DOAC use can help identify those at risk for bleeding, utilizing the expertise of coagulation specialists and specific blood tests to measure drug levels and clotting indicators.
- - If DOAC-related issues are found, experts can recommend tailored solutions, like reducing the dosage or switching to a different anticoagulant medication.
Clinical analysis of bleeding and thrombotic events in haematological-oncology patients with severe thrombocytopenia and a high risk of thrombosis.
Sci Rep
October 2024
Department of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.
Article Synopsis
- The study analyzed haematological oncology patients with severe thrombocytopenia, focusing on factors influencing bleeding and thrombosis risks in those not on anticoagulants.
- Out of 446 patients, it was found that specific clinical features, such as leukemia presence and central venous catheter use, were linked to bleeding, while histories of thrombosis and certain treatments correlated with thrombosis risk.
- Logistic regression revealed lymphoma and minimum platelet count as protective against bleeding, while history of thrombosis and catheter use were identified as significant risk factors for thrombosis.
Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia.
Int J Mol Sci
January 2024
Etablissement Français du Sang PACA-Corse, Aix Marseille University, CNRS, ADES UMR 7268, 13005 Marseille, France.
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) characterized by clonal erythrocytosis and thrombocytosis, respectively. The main goal of therapy in PV and ET is to prevent thrombohemorrhagic complications. Despite a debated notion that red blood cells (RBCs) play a passive and minor role in thrombosis, there has been increasing evidence over the past decades that RBCs may play a biological and clinical role in PV and ET pathophysiology.
View Article and Find Full Text PDFIntroduction: Proton pump inhibitors (PPIs) are known to decrease the risk of gastrointestinal (GI) bleeding. However, concerns have been raised regarding the potential pharmacodynamic interactions of PPIs and antiplatelet drugs with respect to cardiovascular risk. Patients with BCR::ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), and polycythemia vera (PV) often suffer from peptic ulcer disease (PUD) and frequently receive low-dose aspirin due to an intrinsically high thrombotic risk.
View Article and Find Full Text PDFEssential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.
Curr Treat Options Oncol
July 2023
Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy.
Current treatment of essential thrombocythemia (ET) should primarily prevent thrombo-hemorrhagic events, without increasing the rate of fibrotic progression or leukemic evolution, and secondarily control microvascular symptoms. Unlike other classic BCR::ABL1-negative myeloproliferative neoplasms, ET is frequently diagnosed in adolescents and young adults (AYA), defined as individuals aged 15 to 39 years, in up to 20% of patients. However, since the current risk stratification of this disease is based on models, including that of ELN, IPSET-Thrombosis and its revised version, mainly applied to an older patients' population, international guidelines are needed that specifically consider how to evaluate the prognosis of AYAs with ET.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!